CYTOKINETICS, INCORPORATED Depreciation
CYTOKINETICS, INCORPORATED (CYTK) reported Depreciation of $10.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED depreciation for the quarter ending 2018-12-31 was -$359.00K, a 160.85% decline year-over-year.
- CYTOKINETICS, INCORPORATED depreciation for the quarter ending 2018-09-30 was $268.00K, a 40.44% decline year-over-year.
- CYTOKINETICS, INCORPORATED depreciation for the quarter ending 2018-06-30 was $618.00K, a 40.77% increase year-over-year.
- CYTOKINETICS, INCORPORATED depreciation for the quarter ending 2018-03-31 was $673.00K, a 59.86% increase year-over-year.
- CYTOKINETICS, INCORPORATED depreciation for fiscal 2025 was $10.10M, a 6.32% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED depreciation for fiscal 2024 was $9.50M, a 20.17% decline from fiscal 2023.
- CYTOKINETICS, INCORPORATED depreciation for fiscal 2023 was $11.90M, a 105.17% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED depreciation for fiscal 2022 was $5.80M, a 152.17% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.10M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $9.50M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $11.90M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $5.80M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $2.30M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $1.80M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $1.30M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | -$359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | -$91.00K derived: sum of 2 quarters · filed 2020-03-04 | $527.00K derived: sum of 3 quarters · filed 2020-03-04 | $1.20M 10-K · filed 2020-03-04 |
| 2018-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $886.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.56M 10-Q · filed 2018-11-09 | $2.15M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-06-30 | $618.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.29M 10-Q · filed 2018-08-07 | $1.88M derived: sum of 3 quarters · filed 2019-03-07 | $2.33M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-03-31 | $673.00K 10-Q · filed 2018-05-10 | $1.26M derived: sum of 2 quarters · filed 2019-03-07 | $1.71M derived: sum of 3 quarters · filed 2019-03-07 | $2.15M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.04M derived: sum of 2 quarters · filed 2019-03-07 | $1.48M derived: sum of 3 quarters · filed 2019-03-07 | $1.90M 10-K · filed 2019-03-07 |
| 2017-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $889.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.31M 10-Q · filed 2018-11-09 | $1.49M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $439.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $860.00K 10-Q · filed 2018-08-07 | $1.04M derived: sum of 3 quarters · filed 2018-08-07 | |
| 2017-03-31 | $421.00K 10-Q · filed 2018-05-10 | $604.00K derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2016-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $700.00K 10-K · filed 2018-03-05 | ||
| 2016-09-30 | $517.00K 10-Q · filed 2017-11-03 | |||
| 2015-12-31 | $600.00K 10-K · filed 2018-03-05 | |||
| 2014-12-31 | $500.00K 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $400.00K 10-K · filed 2016-03-03 | |||
| 2012-12-31 | $600.00K 10-K · filed 2015-03-06 | |||
| 2011-12-31 | $1.30M 10-K · filed 2014-03-07 | |||
| 2010-12-31 | $1.90M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |